This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

PHASE4CompletedINTERVENTIONAL

Enrollment

111

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2011

Conditions

Myelodysplastic SyndromeThalassemia

Interventions

DRUG

Deferasirox

Trial Locations (2)

Novartis Investigative Site, Moscow

Novartis Investigative Site, Saint Petersburg